Can sentinel node biopsy be skipped altogether?

For some people, yes. Sentinel node biopsy has been the standard way to check armpit lymph nodes in early invasive breast cancer, but research now shows it can be safely left out in carefully chosen groups. The main group is older women, often around seventy or above, with a small, early, hormone receptor positive and HER2 negative cancer, whose armpit nodes look normal on examination and ultrasound. For them, knowing the node result rarely changes treatment, because hormone therapy is usually recommended anyway and chemotherapy is unlikely. Recent trials have also found that some women with small, low-risk cancers and a normal armpit ultrasound, who have breast-conserving surgery with radiotherapy, did just as well without sentinel node biopsy. Skipping the test avoids its small risks, such as arm swelling, numbness and shoulder stiffness, and shortens surgery. Sentinel node biopsy is also generally not needed for DCIS treated by lumpectomy, because DCIS has not spread beyond the ducts. However, it remains important for many people: younger women, larger or higher-grade tumours, HER2 positive or triple negative cancers, and anyone whose node result might change whether chemotherapy, radiotherapy or other treatment is offered. The decision to omit it should be made with your surgeon and oncologist after looking at your whole situation.

Some people can safely skip it

Mainly older women with small, low-risk, hormone-sensitive cancers.

The key question is benefit

If the result would not change treatment, the test may add little.

Many still need it

For higher-risk cancers, node status guides important decisions.

Avoiding surgery sounds appealing, but it involves accepting some uncertainty.

Some node spread will go undetected

A small share of people who skip the test will have cancer in a node. In trials, this rarely led to worse survival, because other treatment still acts on it.

Staging is less complete

Without node results, the stage is estimated. Occasionally this makes later treatment decisions less clear.

Practice is still evolving

Guidelines differ between countries and centres, and long-term data are still maturing for some groups.

What this page cannot tell you

It cannot say whether omitting the test is safe for you. Your team will review your scans, biopsy and health.

If you think omission might apply to you, these questions help structure the conversation.

Would the result change my treatment?

Ask whether chemotherapy, radiotherapy or hormone therapy plans would differ depending on node results.

Has my armpit been scanned?

Ask whether an armpit ultrasound was done and whether any node looked abnormal.

What happens if I change my mind?

Ask whether node checking could still be done later if new information appears, and how that would affect your surgery, recovery and follow-up. Knowing the fallback plan often makes the decision feel less final and easier to agree to.

What are the risks either way?

Ask how likely node spread is for your cancer, and what side effects the biopsy might bring given your health.